Kornimate/medical-research-clean huggingface dataset:
sleep and memory consolidation in adults with attention deficit hyperactivity.

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: attention deficit disorder with hyperactivity is associated with deficits in cognition and sleep. in healthy adults, memory consolidation processes are related to sleep spindle activity in the sleep electroencephalogram. this association is poorly characterized in adults with attention deficit hyperactivity. in this study, the purpose is to characterize sleep microarchitecture disorders through the analysis of different stage of sleep eeg activity during a polysomnographic examination in adult with mixed attention deficit disorder with hyperactivity presentation compared to healthy.


Eligibility criteria:
inclusion criteria for all participants: * age from 18 to 45 years old * affiliated to the french health care system inclusion criteria for attention deficit hyperactivity disorder patients: * meeting diagnostic and statistical manual (dsm)-5 criteria for mixed attention deficit hyperactivity disorder presentation without drug treatment for attention deficit hyperactivity disorder. exclusion criteria for all participant: * people not able to give consent, neurological disease (other than neurodevelopmental disorders; or any other serious disease (cancer, addiction, systemic disease)), untreated sleep apnea, major depression (beck inventory \> 15), untreated restless leg syndrome; pregnancy in progress or wish to become pregnant during the study or breastfeeding woman, drug treatment including benzodiazepine, neuroleptic or antidepressant before inclusion. exclusion criteria for healthy volunteers: * subjective cognitive and/or sleep complaint.

Keywords: sleep memory
study of colchicine resistance in familial mediterranean fever

Conditions: Mediterranean Fever; Colchicine Resistance

Summary: five to 10% of familial mediterranean patients are considered colchicine-resistant (i.e. patients with a persistent inflammatory syndrome, despite taking the maximum tolerated dose of colchicine daily). the recommended treatment in this case is a subcutaneous anti-interleukin 1 biotherapy (anakinra or canakinumab). these treatments are expensive (1,000 to 12,000 euros/month). however, for a patient to be considered colchicine-resistant, compliance with the treatment must be verified. furthermore specific activation of the pyrin inflammasome by clostrioides difficile toxin and the overrepresentation of these bacteria in the stools of our patients led us to systematically search for them in our resistant patients. the demonstration of the involvement of c. difficile in the imbalance of the disease has not yet been published. the colchiresist study aim to better characterize colchicine-resistance by confirming good compliance to treatment with colchicine hair measurement and by looking for clostrioides infection or intestinal dysbiosis.

patients meeting the criteria for colchicine resistance will be included in a follow-up visit. * adherence to colchicine therapy will be assessed by the girerd questionnaire completed by the patient at the inclusion visit. * a blood test is performed including a haemogram, crp and saa, creatinine and proteinuria. * a standard stool analysis on site to look for c. difficile toxin. for research purposes, samples of: * stool. * a strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex, where the growth and integration are relatively constant to avoid variability. * in patients with baldness or bleached hair only: pubic and/or axillary hair will be taken, the samples will then be processed without segmentation. * additional blood (5ml) and urine (2ml) samples for colchicine dosage. the patient's participation ends after this visit

Eligibility criteria:
inclusion criteria: inclusion criteria age ≥ 12 years with no upper age limit -patients with familial mediterranean fever (fmf) meeting international criteria for the disease (livneh criteria) and carrying 2 pathogenic mutations in the mefv gene. patients considered colchicine-resistant according to eular criteria reviewed by an expert consensus: * persistence of signs of activity (at least one attack per month for at least 3 months) despite taking the maximum tolerated dosage of colchicine. * persistence of a biological inflammatory syndrome after exclusion of other causes and despite taking a maximum tolerated dosage of colchicine. * signature of an informed consent by the patient (or his parents if under 18 years of age) * patients affiliated to a social security system exclusion criteria: - patients participating in another interventional trial

Keywords: familial mediterranean fever colchicin-resistant drug compliance microbiota drug resistance clostrioides difficile interleukin-1 second-line therapy.
hematological response in patients with paroxysmal nocturnal hemoglobinuria treated with anti-c5 antibody: an external control arm study for iptacopan use in anti-c5 naïve patients

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: the aim of this non-interventional secondary use of data study is to evaluate hematological response in patients with paroxysmal nocturnal hemoglobinuria and anemia in the 6-month period after initiation of anti-c5 antibody treatment using real-world data obtained from multiple datasets. the results will be used to contextualize results from the appoint-pnh (nct04820530) trial with iptacopan.


Eligibility criteria:
inclusion criteria: 1. incident users of anti-c5 antibody treatment (i.e., first use of anti-c5 antibody with no evidence of use prior to that) 2. confirmed clinical diagnosis of pnh (including pnh clone size \>10% in rbc percent/white blood cell (wbc) percent) 3. adult patients ≥18 years of age 4. baseline hb \<10 g/dl. exclusion criteria: patients who met any of the following criteria were not eligible for inclusion. 1. bone marrow transplantation within one year prior to initiating anti-c5 treatment 2. hereditary complement deficiency 3. reticulocyte count \<60x10\^9/l. 4. pregnancy
comparing the efficacy of pregabalin and hydroxyzine on the anxiety score

Conditions: Feeling Anxious

Summary: the insertion of long-lasting intravenous device is done under local anesthesia. currently, in the investigators hospital, no premedication is given to the patients. however, this procedure occurs in a particular emotional context related to the diagnosis of cancer or malign hemopathies. therefore, administration of a sedative or anxiolytic drugs before the start of the procedure can be questionable. hydroxyzine is the reference molecule for premedication because of its anxiolytic and anti-histaminic properties a new agent, pregabalin, shares also the same properties the main objective of this study was to compare the efficacy of pregabalin and hydroxyzine on the anxiety score as a premedication during the insertion of long-lasting intravenous device under local anesthesia.


Eligibility criteria:
inclusion criteria: * patients aged from 18 to 75 years * patient schedules for insertion of long-lasting intravenous device exclusion criteria: * history of previous insertion of long-lasting intravenous device or central intravenous catheter * long term treatment of gabapentin or pregabalin * hypersensitivity to pregabalin or any of the excipients * hypersensitivity to hydroxyzine, one of its metabolites, one of the excipients, another derivative of piperazine, aminophylline or ethylene diamine. * patient at risk of glaucoma e * patient at risk for urinary retention * patient severe respiratory failure * patient at the general condition not too corrupted (asa iv) * renal failure with creatinin clearance \< 30 ml / min * patient not affiliated to social security * pregnant or lactating * patients in emergency situations * inpatient without consent
identification of anaphylactogenic antibodies in peanut allergy

Conditions: Peanut Allergy

Summary: this project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.

* characterization of patient samples reactivity (sera obtained from blood) against major peanut allergens. * isolation of antibody-producing b cells. * molecular cloning of peanut-specific antibodies from antibody gene sequences obtained from b cells. * biophysical and functional characterization of isolated antibodies

Eligibility criteria:
inclusion criteria: * participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific ige testing) * male and female subjects older than 3 years * written informed consent exclusion criteria: * age below three years * patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.
prospective clinical evaluation of periodontal response to different prosthetic margin design

Conditions: Gingival Recession; Gingival Disease; Gingival Bleeding

Summary: background: the actual literature is consistent in considering potential negative effects of sub-gingival prosthetic margins on the periodontal health, but no research has focused the attention on the type of prosthetic margin designs. hence, the aim of the present study is to evaluate if a horizontal finishing line (deep chamfer preparation) may have a different influence on periodontal soft tissue in comparison with a vertical finishing line (feather edge preparation). methods: a prospective randomized controlled double blind clinical trial with one single operator and three experienced examiners was performed. one hundred and six crowns were prepared with horizontal tooth preparation while ninety-four with vertical tooth preparation. all the margins were positioned within the periodontal sulcus, at 0.5mm sub-gingivally and all the all-ceramic restorations were cemented with resin cement. periodontal probing depth (ppd), plaque index (pi), gingival index (gi) and gingival bleeding on probing (bop) were recorded prior to tooth preparation and twelve month after crown cementation. also, at 12 months follow-up, the gingival margin position was related to the crown margin position.


Eligibility criteria:
inclusion criteria: the patient inclusion criteria were as follows: 1. dentate patients treatment planned for single unit restorations in the esthetic zone (from 1st premolar forward) 2. periodontal probing depth prior to tooth preparation ≤4mm, with no bleeding on probing and no plaque 3. \>30 years of age 4. full mouth plaque score (fmps) and full mouth bleeding scores (fmbs) \<20% at study baseline 5. eventual loss of attachment limited only to areas different from the sites included in the study. the patient exclusion criteria were as follows: 1. patient with medical history in which any dental intervention would be contraindicated 2. any local or systemic disease, condition or medication that might compromise healing and affect the periodontium 3. dental caries or periodontal disease in the remaining teeth 4. inability or unwillingness to return for follow-up visit. exlusion criteria: 1. patients with systemic diseases (such as heart, coagulation, and leukocyte diseases or metabolic disorders) 2. history of radiation therapy in the head and neck region within 12 months prior to surgical phase 3. current treatment with steroids 4. neurological or psychiatric condition that could interfere with good oral hygiene 5. immunocompromised status, including infection with human immunodeficiency virus 6. smoking habit (more than 10 cigarettes/day) 7. drug or alcohol abuse 8. inadequate compliance 9. patients who received bone regeneration procedure
a study of the safety of atezolizumab in patients with advanced or metastatic urothelial carcinoma in argentina

Conditions: Urothelial Carcinoma

Summary: the main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in argentina.


Eligibility criteria:
inclusion criteria: * signed an informed consent form submitted to the administración nacional de medicamentos alimentos y tecnología médica (anmat) * histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra). * have received at least one dose of atezolizumab as per local label and clinical practice. exclusion criteria: * contraindicated atezolizumab therapy
pain assessment during less-invasive-surfactant-administration

Conditions: Infant, Premature, Diseases; Respiratory Distress Syndrome; Surfactant Deficiency Syndrome Neonatal; Pain; Stress

Summary: primary aims of the study are to evaluate the feasibility of skin conductance (sc) measurements and its correlation to neonatal pain and distress scale (n-pass) - scores during the less-invasive-surfactant-administration (lisa)-procedure in preterm infants. secondary aims are to evaluate the effect of lisa on the general stress-level in preterm infants with respiratory distress syndrome. the assessment of pain and stress with sc measurement in addition to the subjective assessment with n-pass may provide more conclusive data on the sensation of pain or stress during the lisa procedure and therefore the necessity of analgosedation. therefore, this study might help to identify those infants in need for analgosedation, which would allow an individualized approach in the future.


Eligibility criteria:
inclusion criteria: * preterm infants ≥27 0/7 weeks of gestation at birth * need for surfactant therapy via lisa according to the local standard operating procedure * ≥27 0/7 weeks of gestation, * within first 48 hours of life * fio2 ≥0.30 to maintain spo2 ≥90% for 15 min, * non-invasive respiratory support with peep 6-8 cmh2o * consent of attending nicu staff for videorecording exclusion criteria: * primary intubation in the delivery room * severe congenital malformation or other conditions requiring immediate endotracheal intubation * insufficient language skills (german or english) of the parents to understand and consent the participation in the study.

Keywords: less-invasive-surfactant-administration skin conductance neonatal pain and sedation scale analgosedation general stress-level
does rectus re-approximation cause adhesion after cesarean section?

Conditions: Obstetric Complication; Muscle Injury

Summary: rectus re-approximation and periton closure are not the obligatory steps during cesarean section. these steps are due to surgeon's preference. however, there is lack of knowledge about the relation of rectus muscle re-approximation and adhesion formation. we are going to study the rectus muscle stiffness by share-wave elastosonography.


Eligibility criteria:
inclusion criteria: * primary cesarean section exclusion criteria: * wound infection

Keywords: elastography rectus muscle re-approximation
interventional bronchoscopy under noninvasive ventilation

Conditions: Noninvasive Positive Pressure Ventilation;; Sedation;; Bronchoscopy；; Interventional；; Central Airway Stenosis

Summary: to evaluate the effect and safety of noninvasive ventilation assisted interventional bronchoscopy for hypoxemia patients with central airway stenosis. with the sedation and analgesia, noninvasive ventilation assisted interventional bronchoscopy for hypoxemia patients with central airway stenosis is safe and effective, carries high satisfaction rate.


Eligibility criteria:
inclusion criteria: * (a)patients with central airway stenosis need interventional bronchoscopy. (b) partial pressure of arterial oxygen (pao2)/fraction of inspired oxygen (fio2) ratio less than 300; exclusion criteria: * (a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(eti) before admission; (f) need for urgent eti due to cardiac or respiratory arrest.
natural ischaemic preconditioning before first myocardial infarction

Conditions: Myocardial Infarction; Angina Pectoris; Coronary Heart Disease; Peripheral Arterial Disease; Cerebrovascular Disease

Summary: there is a sharp rise in the rate of coronary heart disease diagnoses and chest pain consultations in the 90 days before a first heart attack. there is some evidence that chest pain and angina symptoms in this period have a beneficial effect on heart attack outcomes in hospital and shortly after discharge. however, the available evidence is lacking in three key areas. first it is based on a retrospective patient report of symptoms after the heart attack has occurred; this means that patients are required to survive their heart attack and may make errors when reporting prior symptoms. second, evidence for an effect on longer term outcomes, and coronary outcomes in particular (e.g. coronary death, further heart attacks) are unknown. third, there is conflicting evidence that these effects might differ by age, in men and women, and according to treatment in hospital. the investigators hope to address the limitations in the evidence by performing a large, prospective study of the occurrence, timing and effect of different types of symptoms and disease diagnoses occurring before heart attack. the investigators hypothesise that prospectively collected, clinical measures of chest pain symptoms and cardiovascular diagnoses in primary care will have a beneficial effect on short term coronary mortality and may have a beneficial effect on longer term coronary outcomes.


Eligibility criteria:
inclusion criteria: * patients in gprd practices which are deemed "up to standard" by gprd criteria will be included if their practice agreed to be linked to the minap, hes and ons datasets. * patients must have at least one year of gprd "up to standard" registration before the date of first mi. * age over 18. * first myocardial infarction occurring between 1st january 2003 and 31st december 2008, as recorded in the hospital episode statistics data or the myocardial ischaemia national audit project. exclusion criteria: * patients will be excluded if they do not fulfil one of the inclusion criteria.

Keywords: myocardial infarction ischaemic preconditioning myocardial ischaemia national audit project general practice research database hospital episode statistics office for national statistics
m-i/e for preventing vap in post-neurosurgical patients

Conditions: Ventilator Associated Pneumonia; Brain Injuries; Mechanical Insufflation-exsufflation

Summary: ventilator-associated pneumonia (vap) is a common infection in critically ill patients, especially those with acute brain injuries, leading to increased mortality and longer icu stays. the mechanical insufflation/exsufflation (m-i/e) cough assist device improves outcomes in patients with neuromuscular disorders but its effects on brain-injured patients are largely unknown. this study is conducted at a tertiary neurosurgical medical center and consists of two substudies. the prospective physiological study assessed the impact of m-i/e on hemodynamics and icp in mechanically ventilated neurosurgical patients. the combined retrospective-prospective clinical study was performed to investigate the efficacy of m-i/e on occurence of vap and other clinical outcomes.


Eligibility criteria:
inclusion criteria: * post-neurosurgical adult patients * \>18years old * body mass index (bmi) \<35kg/m2) * receiving mechanical ventilation * with arterial blood catheter for continuous pressure measurement and/or ventricular catheter drainage for icp measurement (only for study one) exclusion criteria: * icp \> 22cmh2o or evidence of increased icp * hemodynamically unstable (sbp\ 160 mmhg; dbp \ 110 mmhg, using cardiovascular medicine to maintain pressure, or known cardiac failure) * patients with lung trauma, emphysema, bronchopleural fistula or risk of pneumothorax * history of mechanical ventilation and pneumonia within 6 months before icu admission
mci speech in noise

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to determine whether people with mci (mild cognitive impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. the investigators are also evaluating, within those with mci, whether the hearing tests are associated with neurocognitive functioning. the investigators are interested in learning whether changes in cognition in those with mci can be detected using tests of how the brain processes sound. the investigators hypothesize that participants with mci will score worse on both hearing tests and neurocognitive tests than participants without mci. participants are asked to complete multiple types of hearing tests, take a series of neurocognitive tests, and complete a few questionnaires.


Eligibility criteria:
inclusion criteria: * adults diagnosed with or suspected to have mci (for mci group) or are cognitively normal (for control group) * absence of other risk factors that might affect cap (central auditory processing) performance (e.g., active ear infections, congenital developmental delay, severe hearing loss) * age 55-80 * normal hearing sensitivity (\<40 db hl pure tone average (average of 500, 1000, 2000 hz) thresholds bilaterally * normal middle ear function defined by tympanometry (0.3-2.0 ml) * native english speaker exclusion criteria: * active ear infections or abnormal middle ear pathology * other health condition prohibiting the completion of the cap test battery * mild to profound peripheral hearing loss (\>40 db (decibel) hl (hearing loss) pure tone average (average of 500, 1000, 2000 hz) bilaterally * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * prisoners * history of cns (central nervous system) disorder that might severely impact cognitive function (e.g., alzheimer's disease, parkinson's disease, multiple sclerosis, neurosyphilis, intracranial tumors, history of significant head trauma with loss of consciousness (≥30 min), and cerebrovascular disease) * severe mental illness (e.g., schizophrenia, bipolar disorder) * current, uncontrolled medical condition that could affect cognition (e.g., hypertension) * history of substance use disorder within the (other than nicotine/caffeine) * non-correctable severe hearing or vision loss * use of "cognition enhancing drugs" * frequent, severe headaches (occasional headaches or migraines are fine)
radiomics analysis of focal liver lesions based on contrast-enhanced ultrasound imaging

Conditions: Focal Liver Lesions; Contrast-enhanced Ultrasound

Summary: contrast-enhanced ultrasound (ceus) substantially improves the potential of ultrasound (us) for the identification and characterization of focal liver lesions (flls). compared to contrasted-enhanced mri and ct, it has some unique advantages, such as the absence of ionizing radiation, and easy operability and repeatability. however, the efficacy of ceus in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, and low interobserver agreement. therefore, it is a beneficial attempt to construct an intelligent ceus diagnosis system using digital information technology. this study aims to collect standard data of ceus cines recordings and develop deep learning model for accurate segmentation, detection and classification of liver lesions.


Eligibility criteria:
inclusion criteria: 1. patients with a solid liver tumor visible during routine ultrasound and received ceus. 2. disease history and standard of reference of the lesions can be acquired exclusion criteria: 1. hypersensitivity for ultrasound contrast media 2. pregnant or lactating patients 3. previously treated lesions or local relapse from previously treated lesions 4. diffuse tumors